Status:

COMPLETED

Impact of Ranolazine on Coronary Microcirculatory Resistance

Lead Sponsor:

University of New Mexico

Collaborating Sponsors:

Gilead Sciences

Conditions:

Coronary Microcirculation

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study is being done to determine if Ranolazine treatment improves coronary microcirculation function among patients with coronary microcirculation dysfunction. We are also looking to learn if sym...

Eligibility Criteria

Inclusion

  • \- Patients with subjective symptoms of ischemia without flow limiting angiographic CAD (\<50% epicardial coronary stenosis) and abnormal IMR (\>20 U).
  • Definition of ischemia (any one):
  • chest pain with dynamic ischemic ECG changes (t wave inversions or \> 1 mm ST depressions
  • Exercise treadmill testing induced chest pain with ≥1 mm of downsloping or flat ST segment depression during exercise or recovery; ≥2 mm of ischemic ST depression at a low workload (stage 2 or less or ≤130 beats/min); early onset (stage 1) or prolonged duration (\>5 min) of ST depression; multiple leads (\>5) with ST depression
  • Nuclear stress perfusion defect \> 10%
  • Stress echocardiogram with stress induced wall motion abnormality

Exclusion

  • \- Age \< 18 yrs
  • Flow Limiting epicardial CAD \>50%
  • Life expectancy \< 6 months
  • Recent (\<1 week) myocardial infarction or positive biomarkers
  • Severe aortic stenosis
  • Contraindications to IMR testing including inability to utilize antithrombotic therapy and/or intravenous adenosine
  • Contraindications to Ranolazine therapy:
  • Patients with known hepatic insufficiency, prolonged QT or renal failure (GFR \< 60)
  • use of drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole, macrolides and HIV protease inhibitors
  • Pregnancy, breastfeeding
  • Patients taking drugs which prolong QT interval

Key Trial Info

Start Date :

May 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2016

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT01815957

Start Date

May 1 2012

End Date

March 1 2016

Last Update

December 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of New Mexico Health Science Center

Albuquerque, New Mexico, United States, 87131

Impact of Ranolazine on Coronary Microcirculatory Resistance | DecenTrialz